The effects of vaccination on Johne's disease AGID and ELISA tests were evaluated in a group of 80 goat kids enrolled in a vaccine challenge study. Four vaccine combinations, including cell wall-competent (CWC) alum adjuvant, CWC-QS21 adjuvant, cell wall deficient (CWD) alum adjuvant and CWD-QS21 vaccines were evaluated. Kids were vaccinated at one and four weeks of age with each vaccine or a sham control vaccine consisting of alum adjuvant. Kids were challenged orally with 6.0 X 10⁹ organisms in four divided doses (1.5 X 10⁹ organisms per dose) using a confirmed goat isolate of Mycobacterium avium subsp. paratuberculosis (MAP). Both AGID (Cornell method) and ELISA (Biocor) tests were performed pre-vaccination, post-vaccination/pre-challenge and monthly thereafter. Infection status was determined by combination of necropsy findings and fecal/tissue culture of necropsy tissues. Half the kids within each group were necropsied at 6 months post-challenge and remaining kids were necropsied at 9 months post-challenge. Results indicate overall sensitivity and specificity of AGID and ELISA tests in sham-vaccinated infected and non-infected control kids for all post-challenge samplings were 14.7% and 100% for AGID, and 30.7% and 100% for ELISA. At 6 months post-challenge sensitivity and specificity were 20% and 100% for AGID, and 60% and 100% for ELISA in controls. At 9 months post-challenge sensitivity and specificity were 40% and 100% for AGID and 80% and 100% for ELISA in controls. None of the vaccines resulted in positive AGID or ELISA tests post-vaccination/pre-challenge or affected specificity of either test in any groups. Time to first positive AGID test was reduced by 2 months in all vaccinated groups. Overall AGID sensitivity was approximately doubled in groups given the 2 alum-adjuvanted vaccines irrespective of antigen type. Overall ELISA sensitivity was reduced 6-fold in groups given the CWC MAP vaccines irrespective of adjuvant type.